section name header

Indications

High Alert

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: hypertension, HF, MYOCARDIAL ISCHEMIA/INFARCTION, QT interval prolongation, TORSADES DE POINTES.

Derm: acne, erythema, exfoliative dermatitis, flushing, hand-foot skin reaction, , pruritus, rash, dry skin, impaired wound healing, STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS.

EENT: hoarseness.

F and E: hypocalcemia, hypophosphatemia, hypokalemia.

GI: anorexia, constipation, diarrhea, dyspepsia, dysphagia, mucositis/stomatitis, nausea, HEPATOTOXICITY, lipase/amylase, vomiting.

GU: fertility (males), erectile dysfunction, nephrotic syndrome, proteinuria, renal failure.

Hemat: anemia, bleeding, leukopenia, thrombocytopenia, lymphopenia.

Metab: weight loss.

MS: arthralgia, myalgia.

Neuro: depression, fatigue, neuropathy, weakness.

Resp: INTERSTITIAL LUNG DISEASE.
Misc: pain, (INCLUDING ANGIOEDEMA)HYPERSENSITIVITY REACTIONS .

Interactions

Drug-Drug:

Drug-Natural Products:

Availability

(Generic available)

Route/Dosage

US Brand Names

NexAVAR

Action

Therapeutic Effects:

Classifications

Therapeutic Classification: antineoplastics

Pharmacologic Classification: kinase inhibitors

Pharmacokinetics

Absorption: 38–49% absorbed following oral administration; absorption by high-fat meals.

Distribution: Unknown.

Protein Binding: 99.5%.

Metabolism/Excretion: Primarily metabolized by the liver via the CYP3A4 isoenzyme and UGT1A9; some metabolites are pharmacologically active. Primarily excreted in feces (77%), with 51% being excreted as unchanged drug. 19% excreted in urine, primarily as metabolites.

Half-life: 25–48 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown3 hr12 hr

Patient/Family Teaching

Pronunciation

so-RA-fe-nib